Jianyuan Zhang

Jianyuan Zhang

Auto-generated profile, based on publicly available information

Jianyuan Zhang

Department of Nuclear Medicine, Baoding No. 1 Central Hospital, Baoding, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WMWei Mu
Wei Mu
LJLei Jiang
Lei Jiang
JZJianYuan Zhang
JianYuan Zhang
YSYu Shi
Yu Shi
JGJhanelle E. Gray
Jhanelle E. Gray
MSMatthew Schabath
Matthew Schabath
Two major treatment strategies employed in non-small cell lung cancer, NSCLC, are tyrosine kinase inhibitors, TKIs, and immune checkpoint inhibitors, ICIs. The choice of strategy is based on heterogeneous biomarkers that can dynamically change during therapy. Thus, there is a compelling need to identify comprehensive biomarkers that can be used longitudinally to help guide therapy choice. Herein, we report a 18F-FDG-PET/CT-based deep learning model, which demonstrates high accuracy in EGFR mutation status prediction across patient cohorts from different institutions. A deep learning score (EGFR-DLS) was significantly and positively associated with longer progression free survival (PFS) in patients treated with EGFR-TKIs, while EGFR-DLS is significantly and negatively associated with higher durable clinical benefit, reduced hyperprogression, and longer PFS among patients treated with ICIs. Thus, the EGFR-DLS provides a non-invasive method for precise quantification of EGFR mutation status in NSCLC patients, which is promising to identify NSCLC patients sensitive to EGFR-TKI or ICI-treatments.

12 October 2020 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
JZJianYuan Zhang
JianYuan Zhang
BZBin Zhang
Bin Zhang
QRQingGuo Ren
QingGuo Ren
QZQing Zhong
Qing Zhong
YLYe Li
Ye Li
CZCuiping Zhao
Cuiping Zhao

11 June 2025 in IEEE Access
Verified
Journal Article
Open access
XNXuewei Niu
Xuewei Niu
JZJianyuan Zhang
Jianyuan Zhang
YBYu Bai
Yu Bai
MGMengman Gao
Mengman Gao
XYXin Yang
Xin Yang
Addressing the challenges of inaccurate lung nodule segmentation due to significant scale variations, indistinct boundary textures, and intense background noise, this study introduces a Segment Anything model (SAM)-based feature-enhanced U-Net algorithm for lung nodule segmentation, incorporating the advantages of a Transformer structure and the traditional 3D U-Net framework. Specifically, the Transformer is employed to globally extract structural features of lung nodules and adjacent tissues, whereas a shallow 3D U-Net focuses on capturing image texture characteristics.This manner leverages both structural and texture features for feature enhancement, which are significant for accurate segment the lung nodules.Furthermore, guided by the SAM, the U-Net architecture is refined to assimilate multi-scale information post-feature enhancement, with deep semantic information being re-utilized from the U-Net decoder to achieve precise lung nodule segmentation. The proposed model is evaluated on the LUNA16(Lung Nodule Analysis 2016) and LNDb(Lung Nodule Database) lung nodule segmentation datasets, yielding promising results specifically on the LUNA16 data: Precision achieves 91. 20%, Sensitivity reaches 89. 95%, and the Dice Similarity Coefficient (DSC) achieves 98. 90%. These findings not only showcase the superior performance of our model in lung nodule segmentation, but also underscore its potential to significantly improve segmentation accuracy compared to existing methodologies.

12 February 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
CWCong Wang
Cong Wang
XNXuewei Niu
Xuewei Niu
TXTianyi Xia
Tianyi Xia
PWPeng Wang
Peng Wang
YWYuzhe Wang
Yuzhe Wang
ZXZebin Xiao
Zebin Xiao
Purpose: To evaluate whole-tumor histogram analysis of diffusion kurtosis imaging (DKI), intravoxel incoherent motion (IVIM), and dynamic contrast-enhanced MRI (DCE-MRI) in predicting the efficacy of imatinib, a c-KIT inhibitor, for treating patient-derived models derived from sinonasal mucosal melanomas (MM). Experimental Design: This study included 38 patients with histologically confirmed sinonasal MM, who underwent DKI, IVIM, and DCE-MRI. Patient-derived tumor xenograft models and precision-cut tumor slices were established to evaluate tumor response to imatinib. Whole-tumor histogram analysis was conducted on imaging parameters, and logistic regression models were applied to determine the predictive value of these metrics in differentiating responders from nonresponders. Results: Among the 38 patients with sinonasal MM, 12 were classified as responders and 26 as nonresponders based on patient-derived tumor xenograft and precision-cut tumor slice model responses to imatinib. The DKI model revealed significant differences in mean, median, 10th percentile, and 90th percentile values of Dk and K between responders and nonresponders (P < 0.05). The IVIM model indicated significant differences in 10th percentile and mean values of D, with kurtosis f being a strong predictor. The DCE-MRI model, using the 90th percentile Ktrans metric, demonstrated robust predictive performance, achieving an AUC of 0.89, with 80.77% specificity and 91.67% sensitivity. The combined logistic model integrating DKI, IVIM, and DCE-MRI metrics produced the highest predictive accuracy, with an AUC of 0.90. Conclusions: Whole-tumor histogram analysis of DKI, IVIM, and DCE-MRI offers a noninvasive method for predicting the efficacy of c-KIT inhibitors in sinonasal MMs, presenting valuable implications for guiding targeted treatment in this rare cancer type.